Carbon monoxide releasing molecules and uses thereof

a carbon monoxide and releasing molecule technology, applied in the direction of biocide, organic chemistry, drug compositions, etc., can solve the problems of ineffective carbon monoxide delivery to therapeutic targets by inhalation, inability to achieve clinical application, and high dose requirements for delivering carbon monoxide to therapeutic targets in diseased tissues. likely to be associated with adverse effects

Inactive Publication Date: 2016-05-19
ALFAMA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a new group of compounds called molybdenum CO-RM compounds, which can be used to treat liver disease and inflammatory diseases. These compounds have specific formulas and can be prepared using various methods. The technical effect of this patent is the discovery and validation of new compounds that can be used to treat important medical conditions.

Problems solved by technology

Carbon monoxide administration by inhalation is not practical for clinical applications, as it requires special delivery devices such as ventilators, face masks, tents, or portable inhalers.
Moreover, carbon monoxide delivery to therapeutic targets by inhalation is inefficient, because it involves transport of carbon monoxide by hemoglobin.
Therefore, the doses required to deliver carbon monoxide to therapeutic targets in diseased tissues are likely to be associated with adverse effects.
The identification of CO-RMs that are best suited for the treatment of a particular disease remains a major challenge of CO-RM development.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carbon monoxide releasing molecules and uses thereof
  • Carbon monoxide releasing molecules and uses thereof
  • Carbon monoxide releasing molecules and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Mo Complexes

Synthesis of Mo(CO)3(η6-C7H8)

[0232]The preparation of the molybdenum tri-CO complex Mo(CO)3(η6-C7H8) is described in the literature (see, e.g., W. A. Herrmann and A. Salzer, Synthetic Methods of Organometallic and Inorganic Chemistry, volume 1, Georg Thieme Verlag, New York, 1996, p 129; and Abel et al., J. Chem. Soc. (1958) 4559).

Preparation of Tricarbonyl[tris(isocyanoacetic acid)]Mo(0) (1-b)

[0233]

[0234]Preparation of tricarbonyl[tris(isocyanoacetic acid ethyl ester)]Mo(O) (1-a): Mo(CO)3(η6-C7H8) (2.1 g; 7.72 mmol; 272.1117 g / mol) was dissolved in 40 mL of MeOH to give a red, slightly turbid solution. CNCH2CO2Et (3 eq.; 2.53 mL; 23.15 mmol; 113.11 g / mol; 1.035 g / mL) was dissolved in 20 mL MeOH and added to the previous solution. The red solution immediately turned darker, greenish, and gradually became lighter. The solution was stirred at room temperature for 45 min, when a TLC analysis (hexane:ethyl acetate 1:3) showed that (Mo(CO)3(η6-C7H8)) had been c...

example 2

CO-Release Kinetics

[0275]The CO release kinetics of Compounds 1b, 2b, 3b, 4b, and 5b was performed in vitro in HEPES buffer (pH 7.4) or in phosphate buffer (pH 7.4) and in the presence of liver microsomes. The quantization of the released CO was performed according to Vreman et al. Anal. Biochem. (2005) 341: 280-289 using a Gas Chromatograph with a Reducing Compound Photometer detector (GC-RCP; Peak Laboratories, Mountain View, Calif.), which allows quantifying CO in gas mixtures at concentrations as low as 1-2 parts per billion (ppb).

General Method for the Determination of CO Release in HEPES Buffer

[0276]The CO release kinetics of all compounds was evaluated in 50 mM HEPES buffer (pH 7.4) in a sealed 8-mL vial. Stock solutions (5 mM) of the compounds were prepared in PBS buffer (each compound was soluble in PBS after the addition of 3 equivalents of NaOH) and 10 μL were added to 990 μL of 50 mM HEPES buffer (final concentration in buffer was 50 μM). Since light activation can relea...

example 3

Accumulation of Carbon Monoxide (CO) in Tissues after Administration of Carbon-Monoxide Releasing Molecule

[0298]Carbon monoxide-releasing molecules (CO-RMs) are carriers of carbon monoxide (CO) and can release CO in vivo. CO can bind to hemoglobin in the blood and to various heme proteins in cells. Vreman et al. Anal Biochem 341:280-289 describes a method to release CO bound to tissues into the gas phase, and quantify it using GC-RCP chromatography. We applied this methodology to assay CO in various tissues of mice treated with CO-RMs (see Example 2, herein). However, since the CO release method of Vreman (in vitro incubation with sulfosalicylic acid) also releases CO from the CO-RM, the CO released from tissue samples represents CO bound to tissue proteins and CO from CO-RM compound accumulated in tissue. For CO-RM compounds with slow CO release rates in vivo, the CO measured at the earliest sampling point (5 min after CO-RM administration) may therefore mostly be a measure for the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided herein are novel carbon-monoxide releasing molecules (CO-RMs) of the Formula (I):and esters, amides, salts, solvates and hydrates thereof; wherein R1 and R2 are as described herein. Also provided are pharmaceutical compositions comprising these compounds, methods of their preparation, and their use in the treatment of liver disease and inflammation.

Description

[0001]The present application is a continuation of and claims priority under 35 U.S.C. §120 to U.S. application, U.S. Ser. No. 14 / 112,786, filed Jan. 29, 2014, and entitled “CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF,” which is a national stage filing under 35 U.S.C. §371 of international PCT application, PCT / US2012 / 034264, filed Apr. 19, 2012, and entitled “CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF,” which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 61 / 477,036, filed Apr. 19, 2011, and entitled “CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF,” which are incorporated herein by reference in their entireties for all purposes.FIELD OF THE INVENTION[0002]The instant disclosure relates to carbon monoxide releasing molecules (CO-RMs) and uses thereof to treat liver diseases and inflammatory conditions.BACKGROUND OF THE INVENTION[0003]Carbon monoxide (CO) is the most commonly encountered environmental poison. Paradoxica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07F11/00
CPCC07F11/00A61P1/00A61P1/04A61P1/16A61P29/00
Inventor BLATTLER, WALTER ANTONROMAO, CARLOS J.R.C.RODRIGUES, SANDRA SOFIA PEREIRAKROMER, LUKAS ADRIANOTTERBEIN, LEO EDMONDGALLO, DAVID JOHN
Owner ALFAMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap